https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-23 12:38:252024-07-23 12:38:57Novo Holdings leads $105 million financing of Magenta Medical to support FDA approval for world’s smallest heart pump
https://www.optimumcomms.com/wp-content/uploads/2024/04/Xeltis_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-23 08:42:522024-07-23 11:27:44Xeltis appoints Shawn Gage as Vice President of US Clinical Affairs
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-18 14:32:502024-07-18 14:32:50Novo Holdings Portfolio Company Invetx to be Acquired by Dechra Pharmaceuticals
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-16 10:23:582024-07-16 10:23:584SC receives Orphan Drug Status (ODS) for resminostat (Kinselby) in cutaneous T-cell lymphoma in Switzerland
https://www.optimumcomms.com/wp-content/uploads/2024/01/Vivet_Logo_300x180px-80x80-1.png
758
1104
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-16 09:37:502024-07-16 09:37:50Dr Gloria Gonzalez-Aseguinolaza, Chief Scientific Officer of Vivet Therapeutics Receives the Rosalind Franklin Society Special Award in Science
https://www.optimumcomms.com/wp-content/uploads/2023/02/ASCEneuron_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-16 08:25:152024-07-16 08:25:15Asceneuron Secures $100 Million Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Diseases
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-16 08:17:162024-07-16 08:17:16Novo Holdings leads $100 million Series C financing of Asceneuron to advance groundbreaking therapy for Alzheimer’s disease
https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-11 09:03:192024-07-11 09:03:32Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business
https://www.optimumcomms.com/wp-content/uploads/2024/06/iOnctura_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-09 09:13:242024-07-09 09:26:44iOnctura announces expansion of roginolisib clinical trial program to NSCLC
https://www.optimumcomms.com/wp-content/uploads/2023/02/CurveTx_Logo_300x180px-80x80-Recovered.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-09 08:41:232024-07-09 08:41:23Curve Therapeutics strengthens Leadership Team with appointment of experienced biotech executive Simon Jones
https://www.optimumcomms.com/wp-content/uploads/2023/10/Oxolife_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-08 09:10:482024-07-08 09:10:48A pill for infertility: Oxolife’s non-hormonal oral drug raises embryo implantation rate, pregnancy rates and live birth rate in women undergoing IVF and ICSI, data being presented at ESHRE shows
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-08 07:47:032024-07-08 07:47:03Novo Holdings co-leads £90 million ($114 million) Series A financing for Myricx Bio to advance a novel payload class for antibody-drug conjugates
https://www.optimumcomms.com/wp-content/uploads/2024/03/Mission_Therapeutics_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-02 08:43:532024-07-02 08:43:53Mission Therapeutics awarded $5.2m from The Michael J. Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-01 13:08:222024-07-01 13:08:22Novo Holdings invests in MATR Foods’ expansion within plant-based fungi food
https://www.optimumcomms.com/wp-content/uploads/2023/02/Bionical_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-06-27 12:06:502024-06-27 12:06:50Tom Tacon appointed Business Unit Director of Bionical Virtual Engagement
https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-06-27 08:41:482024-06-27 08:41:48Resolution Therapeutics Receives MHRA Approval to Commence Phase I/II EMERALD Study for Lead Candidate RTX001
https://www.optimumcomms.com/wp-content/uploads/2024/06/Template_Logo_300x180px-80x80Web_Logos.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-06-27 08:05:002024-06-27 08:56:11Fostrox + Lenvima® holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GI
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-06-27 06:00:462024-06-27 08:37:10Novo Holdings and DLG Group join forces to advance sustainable crop production
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-06-25 10:51:202024-06-25 10:51:20Novo Holdings announces investment in AgNext Technologies, an agricultural and food technology company developing AI-based solutions for more sustainable agriculture
https://www.optimumcomms.com/wp-content/uploads/2023/02/AMSilk_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-06-25 10:18:042024-06-25 10:18:04AMSilk to showcase its biofabricated yarns at Première Vision ParisFor more information about Optimum Strategic Communications, please get in touch.
